Cargando…

Correction to: Effectiveness and safety of nivolumab in patients with head and neck cancer in Japanese real‑world clinical practice: a multicentre retrospective clinical study

Detalles Bibliográficos
Autores principales:	Hanai, Nobuhiro, Shimizu, Yasushi, Kariya, Shin, Yasumatsu, Ryuji, Yokota, Tomoya, Fujii, Takashi, Tsukahara, Kiyoaki, Yoshida, Masafumi, Hanyu, Kenji, Ueda, Tsutomu, Hirakawa, Hitoshi, Takahashi, Shunji, Ono, Takeharu, Sano, Daisuke, Yamauchi, Moriyasu, Watanabe, Akihito, Omori, Koichi, Yamazaki, Tomoko, Monden, Nobuya, Kudo, Naomi, Arai, Makoto, Sakurai, Daiju, Asakage, Takahiro, Doi, Issei, Yamada, Takayuki, Homma, Akihiro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Singapore 2021
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8055618/ https://www.ncbi.nlm.nih.gov/pubmed/33837490 http://dx.doi.org/10.1007/s10147-021-01879-y

Ejemplares similares

Effectiveness and safety of nivolumab in patients with head and neck cancer in Japanese real-world clinical practice: a multicenter retrospective clinical study
por: Hanai, Nobuhiro, et al.
Publicado: (2020)

Outcomes of long-term nivolumab and subsequent chemotherapy in Japanese patients with head and neck cancer: 2-year follow-up from a multicenter real-world study
por: Yasumatsu, Ryuji, et al.
Publicado: (2021)

Effectiveness of nivolumab affected by prior cetuximab use and neck dissection in Japanese patients with recurrent or metastatic head and neck cancer: results from a retrospective observational study in a real-world setting
por: Kariya, Shin, et al.
Publicado: (2021)

Single-center prospective study on the efficacy of nivolumab against platinum-sensitive recurrent or metastatic head and neck squamous cell carcinoma
por: Okamoto, Isaku, et al.
Publicado: (2022)

Prognostic Biomarkers of Salvage Chemotherapy Following Nivolumab Treatment for Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma
por: Wakasaki, Takahiro, et al.
Publicado: (2020)

Multicentre, retrospective study of the efficacy and safety of nivolumab for recurrent and metastatic salivary gland carcinoma
por: Niwa, Kazutomo, et al.
Publicado: (2020)

Into the Clinic With Nivolumab and Pembrolizumab
por: Shu, Catherine A., et al.
Publicado: (2016)

Staging of gastric cancer with the Clinical Stage Prediction score
por: Taniguchi, Kiyoaki, et al.
Publicado: (2019)

Interferon Inducible IFI16 Expression in p16 Positive Squamous Cell Carcinoma of the Oropharynx
por: Yamauchi, Moriyasu, et al.
Publicado: (2013)

A Multicenter Phase II Trial of Docetaxel, Cisplatin, and Cetuximab (TPEx) Followed by Cetuximab and Concurrent Radiotherapy for Patients With Local Advanced Squamous Cell Carcinoma of the Head and Neck (CSPOR HN01: ECRIPS Study)
por: Zenda, Sadamoto, et al.
Publicado: (2019)

Two‐year follow‐up of a randomized phase III clinical trial of nivolumab vs. the investigator's choice of therapy in the Asian population for recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141)
por: Yen, Chia‐Jui, et al.
Publicado: (2020)

Effectiveness and safety of weekly paclitaxel and cetuximab as a salvage chemotherapy following immune checkpoint inhibitors for recurrent or metastatic head and neck squamous cell carcinoma: A multicenter clinical study
por: Wakasaki, Takahiro, et al.
Publicado: (2022)

Real-World, Long-Term Outcomes of Nivolumab Therapy for Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck and Impact of the Magnitude of Best Overall Response: A Retrospective Multicenter Study of 88 Patients
por: Matsuki, Takashi, et al.
Publicado: (2020)

Prognostic Markers in Head and Neck Cancer Patients Treated with Nivolumab
por: Nishikawa, Daisuke, et al.
Publicado: (2018)

Hematological predictive markers for recurrent or metastatic squamous cell carcinomas of the head and neck treated with nivolumab: A multicenter study of 88 patients
por: Matsuki, Takashi, et al.
Publicado: (2020)

Clinical utility of nivolumab in the treatment of advanced melanoma
por: Asmar, Ramsey, et al.
Publicado: (2016)

Overexpression of the Orotate Phosphoribosyl-Transferase Gene Enhances the Effect of 5-Fluorouracil in Head and Neck Squamous Cell Carcinoma In Vitro
por: Yasumatsu, Ryuji, et al.
Publicado: (2012)

Advanced Nasopharyngeal Carcinoma: Current and Emerging Treatment Options
por: Jiromaru, Rina, et al.
Publicado: (2022)

The potential clinical utility of cell-free DNA for gastric cancer patients treated with nivolumab monotherapy
por: Inagaki, Chiaki, et al.
Publicado: (2023)

Toxic epidermal necrolysis associated with nivolumab treatment for head and neck cancer
por: Koshizuka, Keiichi, et al.
Publicado: (2020)

Clinical and molecular factors for selection of nivolumab or irinotecan as third-line treatment for advanced gastric cancer
por: Ishii, Takahiro, et al.
Publicado: (2020)

Platinum-based Chemotherapy Plus Cetuximab for the First-line Treatment of Japanese Patients with Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck: Results of a Phase II Trial
por: Yoshino, Takayuki, et al.
Publicado: (2013)

Weekly Cisplatin Plus Radiation for Postoperative Head and Neck Cancer (JCOG1008): A Multicenter, Noninferiority, Phase II/III Randomized Controlled Trial
por: Kiyota, Naomi, et al.
Publicado: (2022)

Immunotherapy for Urothelial Carcinoma: Focus on Clinical Utility of Nivolumab
por: Chiang, Ryan S, et al.
Publicado: (2022)

Eosinophil prognostic scores for patients with head and neck squamous cell carcinoma treated with nivolumab
por: Nishikawa, Daisuke, et al.
Publicado: (2020)

Combination of Ipilimumab and Nivolumab in Cancers: From Clinical Practice to Ongoing Clinical Trials
por: Kooshkaki, Omid, et al.
Publicado: (2020)

Clinical implications of monitoring nivolumab immunokinetics in non–small cell lung cancer patients
por: Osa, Akio, et al.
Publicado: (2018)

First-line pembrolizumab ± chemotherapy for recurrent/metastatic head and neck cancer: Japanese subgroup of KEYNOTE-048
por: Takahashi, Shunji, et al.
Publicado: (2022)

Advanced Lung Adenocarcinoma with Nivolumab-associated Dermatomyositis
por: Kudo, Fumiaki, et al.
Publicado: (2018)

Bicytopenia in Primary Lung Melanoma Treated with Nivolumab
por: Takahashi, Ayumu, et al.
Publicado: (2018)

Clinicopathological and molecular features of responders to nivolumab for patients with advanced gastric cancer
por: Mishima, Saori, et al.
Publicado: (2019)

R-Loop Formation In Trans at an AGGAG Repeat
por: Toriumi, Kazuya, et al.
Publicado: (2013)

Diagnosis and Management of Extracranial Head and Neck Schwannomas: A Review of 27 Cases
por: Yasumatsu, Ryuji, et al.
Publicado: (2013)

Clinical Remission of Cutaneous Squamous Cell Carcinoma of the Auricle with Cetuximab and Nivolumab
por: Chen, Alessandra, et al.
Publicado: (2018)

Nivolumab Induced Thyroid Dysfunction: Unusual Clinical Presentation and Challenging Diagnosis
por: Iadarola, Carmine, et al.
Publicado: (2019)

Emerging treatment options for the management of Hodgkin’s lymphoma: clinical utility of nivolumab
por: Bond, David A, et al.
Publicado: (2017)

Clinical significance of radiotherapy before and/or during nivolumab treatment in hepatocellular carcinoma
por: Yu, Jeong Il, et al.
Publicado: (2019)

A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms
por: Owen, Dwight H., et al.
Publicado: (2023)

Case series of pleomorphic carcinomas of the lung treated with nivolumab
por: Kanazu, Masaki, et al.
Publicado: (2017)

Nivolumab-induced contact dermatitis in a patient with advanced lung cancer
por: Sato, Shintaro, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_5o7m8nesqfusqfg769fl78sfn1